Alzheimer's drug from Biogen to get speedy U.S. review
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Biogen (BIIB) Well Positioned After FDA Grants Priority Review - Canaccord Genuity
August 7, 2020 12:27 PM EDTCanaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating and $350.00 price target on Biogen (NASDAQ: BIIB), citing the FDA granting priority review for aducanumab, the ex-adu pipeline, financial flexibility, and valuation.
The analyst stated "Given the freshness of the news,... More
